دورية أكاديمية
أعرض في EDS

Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery.

التفاصيل البيبلوغرافية
العنوان: Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery.
المؤلفون: Falcone N; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA., Ermis M; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA.; BIOMATEN, Center of Excellence in Biomaterials and Tissue Engineering, Middle East Technical University, Ankara, 06800, Turkey., Tamay DG; BIOMATEN, Center of Excellence in Biomaterials and Tissue Engineering, Middle East Technical University, Ankara, 06800, Turkey.; Department of Biotechnology, Middle East Technical University, Ankara, 06800, Turkey., Mecwan M; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA., Monirizad M; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA., Mathes TG; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA., Jucaud V; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA., Choroomi A; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA., de Barros NR; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA., Zhu Y; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA., Vrana NE; SPARTHA Medical, CRBS 1 Rue Eugene Boeckel, Strasbourg, 67000, France., Kraatz HB; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, M5S 3E5, Canada.; Department of Physical and Environmental Sciences, University of Toronto Scarborough, Toronto, ON, M1C 1A4, Canada., Kim HJ; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA.; College of Pharmacy, Korea University, Sejong, 30019, Republic of Korea., Khademhosseini A; Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA, 90034, USA.
المصدر: Advanced healthcare materials [Adv Healthc Mater] 2023 Oct; Vol. 12 (27), pp. e2301096. Date of Electronic Publication: 2023 Jul 09.
نوع المنشور: Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101581613 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2192-2659 (Electronic) Linking ISSN: 21922640 NLM ISO Abbreviation: Adv Healthc Mater Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Weinheim : Wiley-VCH, 2012-
مواضيع طبية MeSH: Nanostructures*/chemistry , Neoplasms*/therapy, Humans ; Hydrogels/chemistry ; Immunotherapy ; Peptides/chemistry
مستخلص: Peptide-based hydrogel biomaterials have emerged as an excellent strategy for immune system modulation. Peptide-based hydrogels are supramolecular materials that self-assemble into various nanostructures through various interactive forces (i.e., hydrogen bonding and hydrophobic interactions) and respond to microenvironmental stimuli (i.e., pH, temperature). While they have been reported in numerous biomedical applications, they have recently been deemed promising candidates to improve the efficacy of cancer immunotherapies and treatments. Immunotherapies seek to harness the body's immune system to preemptively protect against and treat various diseases, such as cancer. However, their low efficacy rates result in limited patient responses to treatment. Here, the immunomaterial's potential to improve these efficacy rates by either functioning as immune stimulators through direct immune system interactions and/or delivering a range of immune agents is highlighted. The chemical and physical properties of these peptide-based materials that lead to immuno modulation and how one may design a system to achieve desired immune responses in a controllable manner are discussed. Works in the literature that reports peptide hydrogels as adjuvant systems and for the delivery of immunotherapies are highlighted. Finally, the future trends and possible developments based on peptide hydrogels for cancer immunotherapy applications are discussed.
(© 2023 Wiley-VCH GmbH.)
References: Nat Nanotechnol. 2021 May;16(5):538-548. (PMID: 33526838)
Nanoscale. 2017 Sep 28;9(37):14058-14064. (PMID: 28895610)
ACS Appl Mater Interfaces. 2018 Dec 5;10(48):41046-41055. (PMID: 30475573)
J Control Release. 2010 Mar 19;142(3):384-91. (PMID: 19951731)
Front Immunol. 2013 Dec 11;4:438. (PMID: 24376443)
Adv Mater. 2012 Jul 24;24(28):3845-9. (PMID: 22550019)
Nat Commun. 2018 Apr 18;9(1):1532. (PMID: 29670088)
Curr Opin Immunol. 2015 Aug;35:73-9. (PMID: 26163376)
Adv Healthc Mater. 2017 Nov;6(21):. (PMID: 28782184)
Clin Hemorheol Microcirc. 2008;39(1-4):205-12. (PMID: 18503127)
Molecules. 2022 Jan 10;27(2):. (PMID: 35056735)
Chem Commun (Camb). 2019 Oct 10;55(82):12388-12391. (PMID: 31559988)
ACS Biomater Sci Eng. 2021 May 10;7(5):1876-1888. (PMID: 33775089)
Front Immunol. 2018 Nov 28;9:2798. (PMID: 30546367)
Br J Cancer. 2019 Jan;120(1):6-15. (PMID: 30413827)
Nano Lett. 2017 Dec 13;17(12):7447-7454. (PMID: 29172544)
Science. 2010 May 21;328(5981):1031-5. (PMID: 20378772)
Vaccine. 2014 Aug 20;32(37):4743-50. (PMID: 24968155)
J Control Release. 2018 Jul 28;282:120-130. (PMID: 29673645)
Biomater Sci. 2021 Dec 7;9(24):8090-8110. (PMID: 34762077)
ACS Biomater Sci Eng. 2018 Jun 11;4(6):2046-2052. (PMID: 33445275)
Langmuir. 2009 Aug 18;25(16):9447-53. (PMID: 19537819)
Bioact Mater. 2021 Apr 16;6(11):3924-3934. (PMID: 33997486)
RSC Adv. 2020 Apr 6;10(23):13900-13906. (PMID: 35493019)
Nat Rev Clin Oncol. 2022 Apr;19(4):254-267. (PMID: 35082367)
Biomaterials. 2017 Sep;140:16-25. (PMID: 28623721)
Blood Cancer J. 2021 Apr 6;11(4):69. (PMID: 33824268)
MRS Bull. 2014 Jan 1;39(1):25-34. (PMID: 26997752)
Biomaterials. 2021 Jan;265:120401. (PMID: 33002786)
Trends Cancer. 2018 Jun;4(6):418-428. (PMID: 29860986)
Bioact Mater. 2022 Jan 03;16:359-371. (PMID: 35386314)
Biomacromolecules. 2018 Mar 12;19(3):782-792. (PMID: 29384665)
Annu Rev Immunol. 2019 Apr 26;37:173-200. (PMID: 30550719)
Soft Matter. 2019 Feb 20;15(8):1704-1715. (PMID: 30724947)
Biomater Sci. 2022 Jun 14;10(12):3092-3098. (PMID: 35522938)
ACS Biomater Sci Eng. 2019 Sep 9;5(9):4657-4670. (PMID: 33448838)
Bioeng Transl Med. 2017 May 16;2(2):139-155. (PMID: 28932817)
Pharmaceutics. 2022 Dec 01;14(12):. (PMID: 36559179)
Adv Sci (Weinh). 2020 Apr 28;7(11):1903392. (PMID: 32537404)
J Immunother Cancer. 2021 May;9(5):. (PMID: 34016721)
Adv Drug Deliv Rev. 2017 May 15;114:184-192. (PMID: 28712923)
Nano Lett. 2019 Mar 13;19(3):1719-1727. (PMID: 30724087)
Cells. 2021 Sep 10;10(9):. (PMID: 34572028)
Annu Rev Pathol. 2021 Jan 24;16:167-198. (PMID: 33264572)
Cell Mol Immunol. 2017 Aug;14(8):662-674. (PMID: 28626234)
Nat Rev Cancer. 2021 May;21(5):298-312. (PMID: 33750922)
Biomacromolecules. 2021 Sep 13;22(9):3992-4003. (PMID: 34464095)
Adv Healthc Mater. 2013 Oct;2(10):1388-400. (PMID: 23554376)
Angew Chem Int Ed Engl. 2017 Oct 16;56(43):13288-13292. (PMID: 28837256)
Int J Mol Sci. 2022 Mar 03;23(5):. (PMID: 35269922)
Sci Adv. 2022 Jul 22;8(29):eabm7833. (PMID: 35857833)
Cancer J. 2011 Sep-Oct;17(5):359-71. (PMID: 21952287)
Biomaterials. 2021 Jan;268:120549. (PMID: 33278685)
Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. (PMID: 28975930)
ACS Nano. 2018 Oct 23;12(10):9693-9701. (PMID: 30183253)
Biomaterials. 2021 May;272:120767. (PMID: 33813259)
Gels. 2022 Nov 01;8(11):. (PMID: 36354614)
ACS Appl Mater Interfaces. 2014 Apr 23;6(8):5558-65. (PMID: 24660962)
J Control Release. 2017 Dec 28;268:176-183. (PMID: 29056443)
Curr Opin Struct Biol. 2020 Aug;63:97-105. (PMID: 32512499)
Adv Healthc Mater. 2013 Jan;2(1):72-94. (PMID: 23225517)
Nat Mater. 2015 Jun;14(6):643-51. (PMID: 25985456)
Sci Adv. 2022 Jan 21;8(3):eabj0305. (PMID: 35044831)
Int J Mol Sci. 2011;12(9):5736-46. (PMID: 22016623)
Adv Drug Deliv Rev. 2017 Feb;110-111:65-79. (PMID: 27535485)
Cancer Immunol Res. 2017 Mar;5(3):222-233. (PMID: 28143806)
Biomacromolecules. 2014 Sep 8;15(9):3246-52. (PMID: 25102223)
Sci Adv. 2020 Aug 07;6(32):eaba0995. (PMID: 32821819)
Acta Biomater. 2019 Sep 1;95:3-31. (PMID: 30481608)
Polymers (Basel). 2021 Jul 03;13(13):. (PMID: 34279352)
ACS Biomater Sci Eng. 2020 Sep 14;6(9):4774-4798. (PMID: 33455212)
BMC Med. 2016 May 05;14:73. (PMID: 27151159)
Trends Biotechnol. 2016 Jun;34(6):470-482. (PMID: 27138899)
Adv Mater. 2017 Feb;29(5):. (PMID: 27859662)
Bioact Mater. 2017 Sep 06;3(1):118-128. (PMID: 29744449)
J Control Release. 2017 Jun 10;255:81-93. (PMID: 28408199)
J Mater Chem B. 2022 Sep 28;10(37):7183-7193. (PMID: 35348177)
Science. 2013 Dec 20;342(6165):1432-3. (PMID: 24357284)
Acta Biomater. 2018 Mar 15;69:107-119. (PMID: 29248638)
Cancer Gene Ther. 2022 Jan;29(1):10-21. (PMID: 33603130)
Semin Oncol. 2012 Jun;39(3):276-86. (PMID: 22595050)
Anal Chem. 2021 May 18;93(19):7355-7361. (PMID: 33957042)
Pharmacol Res. 2022 Jan;175:106036. (PMID: 34920118)
J Am Chem Soc. 2022 Sep 14;144(36):16512-16523. (PMID: 36049084)
Adv Healthc Mater. 2014 Nov;3(11):1898-908. (PMID: 24923735)
Biomacromolecules. 2017 Nov 13;18(11):3563-3571. (PMID: 28828862)
Biomacromolecules. 2020 Apr 13;21(4):1613-1624. (PMID: 32091881)
J Clin Neurosci. 2018 Oct;56:163-168. (PMID: 30041899)
Biomaterials. 2020 Feb;231:119667. (PMID: 31855625)
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):622-7. (PMID: 20080728)
Biotechnol Adv. 2017 Sep;35(5):575-596. (PMID: 28522213)
Nat Biotechnol. 2016 Mar;34(3):345-52. (PMID: 26807527)
Crit Rev Immunol. 2012;32(6):463-88. (PMID: 23428224)
J Am Chem Soc. 2013 Jul 3;135(26):9907-14. (PMID: 23742714)
Biomacromolecules. 2017 Nov 13;18(11):3514-3523. (PMID: 28721731)
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58. (PMID: 26598942)
Adv Mater. 2018 Jul;30(28):e1801527. (PMID: 29786888)
Macromol Biosci. 2022 Jun;22(6):e2200043. (PMID: 35332672)
J Hematol Oncol. 2019 Nov 28;12(1):126. (PMID: 31779642)
ACS Appl Mater Interfaces. 2018 Apr 18;10(15):12474-12484. (PMID: 29584396)
Angew Chem Int Ed Engl. 2011 Feb 11;50(7):1635-9. (PMID: 21308921)
Adv Healthc Mater. 2018 Jun;7(12):e1701324. (PMID: 29577678)
Biomater Sci. 2020 Jun 21;8(12):3522-3535. (PMID: 32452474)
Biomacromolecules. 2017 Nov 13;18(11):3621-3629. (PMID: 28953367)
Langmuir. 2017 Apr 4;33(13):3234-3240. (PMID: 28282150)
Macromol Biosci. 2021 Jun;21(6):e2100049. (PMID: 33871152)
Curr Opin Immunol. 2014 Apr;27:46-52. (PMID: 24534448)
Nat Commun. 2019 Nov 27;10(1):5408. (PMID: 31776331)
Biomacromolecules. 2017 Nov 13;18(11):3541-3550. (PMID: 28825801)
Nat Rev Cancer. 2004 Jan;4(1):11-22. (PMID: 14708024)
Nat Commun. 2022 Jun 28;13(1):3703. (PMID: 35764641)
ACS Nano. 2013 May 28;7(5):3926-38. (PMID: 23631767)
Materials (Basel). 2022 Aug 25;15(17):. (PMID: 36079250)
Chemistry. 2018 Sep 25;24(54):14316-14328. (PMID: 29667727)
Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):49. (PMID: 30263032)
Biomater Sci. 2018 May 29;6(6):1480-1491. (PMID: 29623975)
Biomaterials. 2020 Oct;256:120216. (PMID: 32736171)
Adv Drug Deliv Rev. 2022 Aug;187:114401. (PMID: 35750115)
Cancers (Basel). 2011 Oct 13;3(4):3856-93. (PMID: 24213115)
Biomaterials. 2017 Jul;134:117-127. (PMID: 28458029)
Mol Pharm. 2019 Jun 3;16(6):2326-2341. (PMID: 31026168)
Nat Rev Cancer. 2021 Aug;21(8):481-499. (PMID: 34083781)
J Control Release. 2021 Feb 10;330:1208-1219. (PMID: 33229053)
Indian J Med Res. 2013 Nov;138(5):779-95. (PMID: 24434331)
J Hematol Oncol. 2022 Mar 18;15(1):28. (PMID: 35303904)
Front Immunol. 2021 Jun 30;12:696791. (PMID: 34276688)
Sci Adv. 2020 Apr 29;6(18):eaaz8985. (PMID: 32490201)
Nano Lett. 2018 Jul 11;18(7):4377-4385. (PMID: 29932335)
Adv Sci (Weinh). 2020 Mar 20;7(9):1903718. (PMID: 32382486)
ACS Omega. 2023 Jan 30;8(5):4677-4686. (PMID: 36777619)
Stem Cell Rev Rep. 2019 Oct;15(5):619-636. (PMID: 31161552)
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17867-72. (PMID: 15601762)
Biomaterials. 2017 Dec;149:1-11. (PMID: 28982051)
J Clin Invest. 2017 Jun 1;127(6):2176-2191. (PMID: 28436934)
ACS Nano. 2018 Apr 24;12(4):3295-3310. (PMID: 29558107)
Curr Pharm Biotechnol. 2018;19(1):5-18. (PMID: 29667553)
ACS Appl Mater Interfaces. 2016 Sep 28;8(38):25036-42. (PMID: 27598654)
Adv Healthc Mater. 2016 Oct;5(20):2575-2594. (PMID: 27593734)
Biomaterials. 2010 May;31(13):3479-91. (PMID: 20138663)
Nat Rev Drug Discov. 2021 Jul;20(7):531-550. (PMID: 33972771)
Adv Mater. 2020 Oct;32(39):e2003310. (PMID: 32820582)
Sci Adv. 2022 Apr 8;8(14):eabn8264. (PMID: 35394838)
Vaccines (Basel). 2022 Dec 27;11(1):. (PMID: 36679904)
Nat Rev Cancer. 2018 Aug;18(8):485-499. (PMID: 29703913)
Adv Ther (Weinh). 2021 Aug;4(8):. (PMID: 34734110)
J Hematol Oncol. 2018 Feb 13;11(1):22. (PMID: 29433552)
Biomaterials. 2018 Mar;159:119-129. (PMID: 29324304)
Vaccines (Basel). 2022 Jan 17;10(1):. (PMID: 35062791)
Chem Rev. 2020 Mar 25;120(6):3210-3229. (PMID: 31804810)
Biomaterials. 2021 Jun;273:120825. (PMID: 33901731)
Front Chem. 2020 Jul 21;8:500. (PMID: 32850613)
Virchows Arch. 2019 Apr;474(4):449-461. (PMID: 30470934)
Adv Drug Deliv Rev. 2021 Jul;174:482-503. (PMID: 34015417)
ACS Appl Mater Interfaces. 2018 Jun 20;10(24):20256-20270. (PMID: 29808986)
ACS Nano. 2010 Jun 22;4(6):3073-86. (PMID: 20507158)
Biomater Sci. 2020 Oct 21;8(20):5601-5614. (PMID: 32832942)
Adv Mater. 2014 Oct;26(38):6530-41. (PMID: 25155610)
Theranostics. 2019 May 24;9(11):3388-3397. (PMID: 31244959)
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7919-E7928. (PMID: 28874575)
Biomater Sci. 2022 Oct 25;10(21):6217-6229. (PMID: 36102692)
Biomaterials. 2013 Nov;34(34):8776-85. (PMID: 23953841)
Theranostics. 2019 Apr 12;9(8):2299-2314. (PMID: 31149045)
Front Immunol. 2021 Mar 09;12:636568. (PMID: 33767702)
J Interferon Cytokine Res. 2019 Jan;39(1):6-21. (PMID: 29889594)
Bioact Mater. 2022 May 13;19:678-689. (PMID: 35600970)
معلومات مُعتمدة: R01 CA257558 United States CA NCI NIH HHS; R01 DK130566 United States DK NIDDK NIH HHS; R01 HL137193 United States HL NHLBI NIH HHS; R01 HL140951 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: adjuvants; biomaterials; cancer immunotherapy; immunomaterials; peptide hydrogels; supramolecular assembly; vaccines
المشرفين على المادة: 0 (Hydrogels)
0 (Peptides)
تواريخ الأحداث: Date Created: 20230531 Date Completed: 20231030 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC10615713
DOI: 10.1002/adhm.202301096
PMID: 37256647
قاعدة البيانات: MEDLINE
الوصف
تدمد:2192-2659
DOI:10.1002/adhm.202301096